224 related articles for article (PubMed ID: 28782487)
1. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
[TBL] [Abstract][Full Text] [Related]
2. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
[TBL] [Abstract][Full Text] [Related]
3. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
6. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
9. The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
O'Connell KE; Mok T; Sweeney B; Ryan AM; Dev KK
Autoimmunity; 2014 Dec; 47(8):505-11. PubMed ID: 24974887
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
11. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE; Zhao Z; Stebbins CC; Cadavid D; Buko AM; Whalley ET; Davis JA; Versage EM; Richert JR; Axtell RC; Steinman L; Medori R
Neurology; 2012 Aug; 79(6):531-7. PubMed ID: 22573631
[TBL] [Abstract][Full Text] [Related]
12. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
13. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
[TBL] [Abstract][Full Text] [Related]
14. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
Zurawski J; Flinn A; Sklover L; Sloane JA
J Neurol; 2016 Aug; 263(8):1511-7. PubMed ID: 27193310
[TBL] [Abstract][Full Text] [Related]
15. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
[TBL] [Abstract][Full Text] [Related]
16. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
[TBL] [Abstract][Full Text] [Related]
17. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
18. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
[TBL] [Abstract][Full Text] [Related]
19. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]